Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Sarah Cannon to Present Latest Cancer Research Insights at ASCO®20 Virtual Meeting


 

Sarah Cannon announced that it will present its latest cancer research insights at the American Society of Clinical Oncology's (ASCO®) Annual Meeting being held virtually May 29 - 31, 2020. This year, Sarah Cannon's drug development and research expertise is featured through more than 110 abstracts and presentations, including data from more than 50 phase 1 studies.

The ASCO®20 Virtual Meeting will bring together the largest community of oncology leaders worldwide to discuss pivotal clinical research that is influencing the latest care and treatment standards for patients facing cancer. This year's event is being led by Sarah Cannon's President of Clinical Operations and Chief Medical Officer, Howard A. "Skip" Burris III, MD, FACP, FACSO, who is serving as the 2020 ASCO® President.

"When I chose my presidential theme to Unite and Conquer: Accelerating Progress Together, I never imagined what new meaning it would take over the course of this year, especially in the time of a global pandemic," says Dr. Burris. "In spite of recent challenges, we know that by bringing together oncologists, pharmacists, nurses, staff, lab techs, scientists, practice administrators and academic researchers, we are more united than ever with our patients to accelerate progress in the fight against cancer."

Dr. Burris will deliver this year's presidential speech on Saturday, May 30 at 8:30 AM CT.

Melissa Johnson, MD, Sarah Cannon's Associate Director of Lung Cancer Research and Drug Development, serves as this year's ASCO® Scientific Committee Chair, leading the scientific program at the meeting. In this role, Dr. Johnson will lead two key programs: the clinical science symposium on "Cancer Care in the Time of COVID: Assessing Impact and Future Direction" on Saturday, May 30 from 3:30-4:30 PM CT, and will also chair the Plenary Session on Sunday, May 31 from 12-2:30 PM CT.

A number of Sarah Cannon research leaders will also participate in the following educational and oral presentations:

  • Johanna Bendell, MD, Chief Development Officer and Director of the GI Cancer Research Program, will present "Phase I Monotherapy Dose Escalation of RGX-202, a First-In-Class Oral Inhibitor of the SLC6a8/CKB Pathway, in Patients with Advanced Gastrointestinal Solid Tumors" in an oral presentation. (Abstract 3504)
  • Jesus Berdeja, MD,Director of Myeloma Research and Senior Investigator of Hematologic Malignancies, is the discussant on the plenary session focused on "Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma" on Sunday, May 31 from 12-2:30 PM CT. Dr. Berdeja will also highlight data in an oral presentation on "Update of CARTITUDE-1: A Phase Ib/II Study of JNJ-4528, a B-Cell Maturation Antigen-Directed CAR-T-Cell Therapy, in Relapsed/Refractory Multiple Myeloma." (Abstract 8505)
  • Ian Flinn, MD, Director of Lymphoma Research, is the discussant during the poster presentation on "Reassessing PI3K Inhibitors in Indolent Lymphomas."
  • Stephanie Graff, MD, Director of the Breast Cancer Program and Clinical Research for Sarah Cannon Cancer Institute at HCA Midwest Health, is the discussant on the poster presentation of "Mind the Gap: Identifying Disparities and Actionable Insights."
  • Anthony Greco, MD, Co-founder of Sarah Cannon, is the discussant during the clinical science symposium on "Redefining Cancer of Unknown Primary: Is Genomics the Answer?" on Saturday, May 30, from 2:30-3:30 PM CT.
  • Erika Hamilton, MD, Director of the Breast Cancer and Gynecologic Cancer Research Program, will review key advancements in breast cancer research during the "Highlights of the Day" session on Saturday, May 30 9:30-10 AM CT.
  • Johnson will present "CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results from a First-In-Human Study in Patients with Advanced Cancer" and "Primary Analysis of a Randomized, Double-Blind, Phase II Study of the Anti-TIGIT Antibody Tiragolumab Plus Atezolizumab Versus Placebo Plus Atezo as First-Line Treatment in Patients with PD-L1-Selected NSCLC (CITYSCAPE)" in two oral presentations. (Abstract 3502, Abstract 9503)
  • Aravind Ramakrishnan, MD, Medical Director of the Bone Marrow Transplant and Cellular Therapy Program for Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, will present "Phase I Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T-Cell Therapy, with Pembrolizumab in Patients with Relapsed/Refractory DLBCL" in an oral presentation. (Abstract 8001)
  • David Spigel, MD, Chief Scientific Officer and Director of the Lung Cancer Research Program, will be the discussant in a plenary session focused on "Osimertinib as Adjuvant Therapy in Patients with Stage IB-IIIA EGFR Mutation Positive NSCLC After Complete Tumor Resection: ADAURA" on Sunday, May 31, from 12-2:30 PM CT.

At the ASCO®20 Virtual Meeting, posters with Sarah Cannon experts as first authors will be presented by:

  • Bendell will present on "First-In-Human Phase I Study of HPN424, a Tri-Specific Half-Life Extended PSMA-Targeting T-Cell Engager in Patients with Metastatic Castration-Resistant Prostate Cancer." (Abstract 5552)
  • Hamilton will present on "Clinical Activity of MCLA-128, Trastuzumab, and Vinorelbine in HER2 Amplified Metastatic Breast Cancer Patients who Had Progressed on Anti-HER2 ADCs." (Abstract 3093)
  • Johnson will present "Safety of BI 754111, an Anti-LAG-3 Monoclonal Antibody, in Combination with BI 754091, an Anti-PD-1 Mab, in Patients with Advanced Solid Tumors." (Abstract 3063)
  • Spigel will present in two posters on "Randomized Phase II Study of Pembrolizumab Alone Versus Pegilodecakin in Combination with Pembrolizumab as First-Line Therapy in Patients with Stage IV Non-Small Cell Lung Cancer with High PD-L1 Expression (CYPRESS 1)" and "RESILIENT Part I, an Open-Label, Safety Run-In of Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Have Progressed with Platinum-Based First-Line Therapy: Subgroup Analyses By Platinum Sensitivity." (Abstract 9563, Abstract 9069)
  • Denise Yardley, MD, Senior Investigator of the Breast Cancer Research Program, will present on "Overall Survival in Patients with Advanced Breast Cancer with Visceral Metastases, Including Those with Liver Mets, Treated with Ribociclib Plus Endocrine Therapy in the MONALEESA -3 and -7 Trials." (Abstract 1054)
  • Manish Patel, MD,Director of Drug Development for Sarah Cannon Research Institute at Florida Cancer Specialists, will present on "A Phase I Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Durvalumab." (Abstract 3092)
  • Carlos Bachier, MD, Director of Cellular Therapy Research, will present on "Outpatient Treatment with Lisocabtagene Maraleucel Across a Variety of Clinical Sites From Three Ongoing Clinical Studies in Relapsed/Refractory Large B-Cell Lymphoma." (Abstract 8037)
  • Debra Richardson, MD, Stephenson Cancer Center at the University of Oklahoma, will present on "Phase I Expansion Study of XMT-1536, a Novel NaPi2b-Targeting Antibody-Drug Conjugate: Preliminary Efficacy, Safety, and Biomarker Results in Patients with Previously Treated Metastatic Ovarian Cancer or Non-Small Cell Lung Cancer." (Abstract 3549)
  • Gerald Falchook, MD, MS, Director of Drug Development for Sarah Cannon Research Institute at HealthONE, will present on "Pen-866, a Miniature Drug Conjugate of a Heat Shock Protein 90 (HSP90) Ligand Linked To SN38 For Patients with Advanced Solid Malignancies: Phase I and Expansion Cohort Results." (Abstract 3515)
  • Elisa Fontana, MD, Clinical Research Fellow at Sarah Cannon Research Institute - UK, will present on "Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer With Or Without Oxaliplatin: Individual Patient Data Meta-Analysis of Three Randomized Controlled Trials with Subgroup Analyses of Age Cohorts." (Abstract 4074)
  • Andrew McKenzie, PhD, Senior Manager of Personalized Medicine,will present on "Clinical and Genomic Analysis of Non-Small Cell Lung Cancer Patients with MET Exon14 Skipping (METex14) Mutations and Responses To Anti-MET Therapy." (Abstract 9613)

The researchers represent Sarah Cannon's global network of strategic sites:

Sarah Cannon Research Institute at Tennessee Oncology, Sarah Cannon Research Institute at Florida Cancer Specialists, Colorado Blood Cancer Institute, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Sarah Cannon Center for Blood Cancer at TriStar Centennial, Sarah Cannon Research Institute at HCA Midwest Health (Kansas City), Sarah Cannon Research Institute at HealthONE (Denver), Sarah Cannon Research Institute - United Kingdom, Sidney Kimmel Cancer Center at Jefferson Health, and The Stephenson Cancer Center at the University of Oklahoma.

Share:

 

Email Print

 

More Grand Rounds:

 

AMA Expands Online Education Hub to Further Streamline the Lifelong Learning, Licensure and Certification Needs of Physicians and Health Care Professi

AMA Expands Online Education Hub to Further Streamline the Lifelong Learning, Licensure and Certification Needs of Physicians and Health Care Professi

AMA Ed HubTM features new educational content from American Society of Addiction Medicine, Obesity Medicine Association, and the Society of Hospital Medicine and offers auto-reporting by American Board of Pathology to help physicians and health professionals improve care delivery

Read More

In light of the coronavirus pandemic, Meharry Medical College School of Dentistry graduates received academic achievement awards recognition in a creative way.

Read More

TriStar StoneCrest Debuts Scar-Free Transoral Thyroidectomy

The surgical team at TriStar StoneCrest Medical Center, under the direction of general surgeon, Joshua Taylor, MD, FACS, with The Surgical Clinic, has become the first in Tennessee to remove thyroid glands using an approach that leaves no visible scar. Rather than performing the surgery through an incision in the neck, which leaves a visible scar, this new scar-free minimally invasive approach was performed using very small incisions inside the mouth, between the gums and lower lip.

Read More

TJC Welcomes Mika Moser as COO

TJC Welcomes Mika Moser as COO

The Tennessee Justice Center recently Mika Moser as chief operating officer. Moser will manage operations at TJC, a nonprofit public interest law firm and advocacy center serving families throughout the state.

Read More

Wishes Granted

Wishes Granted

On June 16, two Vanderbilt University Medical Center physician scientists were each awarded a $220,000 grant to fund separate clinical research efforts to study diabetes. Only six fellows were selected nationally for the highly competitive grant competition to win 2020 Doris Duke Physician Scientist Fellowships ... and two hailed from VUMC.

Read More

HMP, SC&H Capital Enter Joint Venture

SC&H Capital, a leading investment banking and advisory firm has ntered into a joint venture with two healthcare consulting firms, Nashville-based Healthcare Management Partners (HMP) and Baltmore-based i3 Healthcare Consulting, to better serve the strategic and financial needs of the healthcare industry.

Read More

Martin Appointed EVP of Enterprise Technology for Change Healthcare

Martin Appointed EVP of Enterprise Technology for Change Healthcare

In late spring, Change Healthcare announced the appointment of Steven Martin as executive vice president of enterprise technology. Martin joined Change Healthcare from GE where he served as acting CEO for GE Digital. He previously spent over a decade at Microsoft where he was a key leader on their Azure cloud platform team.

Read More

PathGroup Selected as Early Access Partner for Launch of Illumina's Sequencing-Based COVID-19 Diagnostic Test

In June, Nashville-based PathGroup, one of the nation's largest private providers of pathology, clinical and molecular laboratory services, announced the company has been selected as an early access partner for the launch of Illumina's new sequencing-based COVID-19 test. COVIDSeq™ accommodates more than 3,000 test samples per run, allowing for a substantial increase in testing capacity.

Read More

American Airlines Taps into VUMC Expertise

Taking new actions that focus on the well-being and safety of customers and team members, American Airlines announced in late June that it has created a new Travel Health Advisory Panel that includes Vanderbilt University Medical Center (VUMC) infectious disease experts to advise on health and cleaning matters as travelers return over the summer.

Read More

TriStar Health Establishes Uninsured Assistance Hotline

TriStar Health Establishes Uninsured Assistance Hotline

TriStar Health and HCA Healthcare have established a health insurance coverage hotline to assist those whose insurance coverage has been impacted by a life-changing event, such as job loss or reduced income, as a result of the economic impact caused by COVID-19.

Read More

Ardent Health Services Selects American Red Cross Resuscitation Suite™ Program in Enterprise-wide Agreement with HealthStream

Innovative competency-based approach to resuscitation training at Ardent raises the bar on quality and empowers their workforce to improve patient outcomes

Read More

CET Life Sciences Center Welcomes Advansta As New Tenant

Cumberland Emerging Technologies, Inc. (CET) today announced that Advansta, a leading developer and supplier of protein characterization products, has established operations at the CET Life Sciences Center.

Read More

Study Finds Newborn Opioid Withdrawal Rates Show Evidence of Stabilizing

Read More

Heart Transplant Recipient to Bike 120 Miles for Multiple Sclerosis

Heart Transplant Recipient to Bike 120 Miles for Multiple Sclerosis

56-year-old Robert Marcom bikes 20 to 30 miles on a typical weekday morning. On weekends, 70-mile rides are pretty normal accomplishments for Robert.

Read More

Ascension Saint Thomas Proposes State's First Neighborhood Hospital

Ascension Saint Thomas Proposes State's First Neighborhood Hospital

Read More

Let's Give Them Something to Talk About!

Let's Give Them Something to Talk About!

Awards, Honors, Achievements

Read More

American College of Surgeons joins Surgical Care Coalition

Read More

Prevent Child Abuse Tennessee provides guidance for talking with children about race and anti-racism

Widespread protests in response to the murder of George Floyd by a Minneapolis police officer and countless other unjust killings of Black Americans throughout our country's history have brought the issues of racism and racial injustice to the forefront of family conversations.

Read More

Susan R. Bailey, M.D., inaugurated as 175th president of the AMA

Texas allergist becomes third consecutive woman to hold office

Read More

South Carolina Family Physician Chosen as AMA President-elect

The American Medical Association (AMA) today announced the election of Gerald E. Harmon, M.D., a family medicine physician from Pawleys Island, S.C., as the new president-elect of the nation's premier physician organization.

Read More

 
 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: